Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.35 |
| ▸ | CA2 | P00918 | 2/20 | 0.35 |
| ▸ | CA4 | P22748 | 2/20 | 0.35 |
| ▸ | CA6 | P23280 | 2/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | RECQL | P46063 | 1/20 | 0.32 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.31 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1193803 | 0.79 | CA1 (0.40) | CA1CA2CA4CA6CYP3A4 | |
| SCHEMBL28582635 | 0.79 | CA1 (0.35) | CA1CA2CA4CA6CYP3A4 | |
| SCHEMBL9144627 | 0.67 | CA1 (0.33) | CA1CA2CA4CA6CYP3A4 | |
| SCHEMBL320975 | 0.65 | — | — | |
| SCHEMBL2325097 | 0.64 | IDO1 (0.35) | — | |
| SCHEMBL9732647 | 0.63 | — | — | |
| SCHEMBL1639523 | 0.63 | — | — | |
| SCHEMBL3646664 | 0.62 | ERN1 (0.31) | — | |
| SCHEMBL17138418 | 0.62 | — | — | |
| SCHEMBL1303545 | 0.62 | ACHE (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8552067-B2 | poly(imino-keto-methylene/amine) derivatives as a bioactive part in conjugates; diarrhea caused by pathogens: Vibrio cholerae, Clostridium difficile, Escherichia coli, Shigella, Salmonella, rotavirus; or enterotoxins: cholera toxin, E. coli toxin, Salmonella toxin | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-10-08 | — | — | US | claimed |
| US-20110119775-A1 | HYDRAZIDE-CONTAINING CFTR INHIBITOR COMPOUNDS AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-05-19 | — | — | US | claimed |
| US-7888332-B2 | Hydrazide-containing CFTR inhibitor compounds and uses thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-02-15 | — | — | US | claimed |
| EP-2117601-A2 | MACROMOLECULAR CONJUGATES OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR PROTEIN INHIBITORS AND USES THEREOF | The Regents of the University of California (US) | 2009-11-18 | — | — | EP | claimed |
| EP-1740532-A4 | HYDRAZIDE-CONTAINING CFTR INHIBITOR COMPOUNDS AND USES THEREOF | UNIV CALIFORNIA (US) | 2009-06-10 | — | — | EP | claimed |
| US-7414037-B2 | cystic fibrosis transmembrane conductance regulator protein inhibitor; 2-naphthalenylamino-[(3,5-dibromo-2,4-dihydroxyphenyl)methylene][3-[4-(3-(PEG)n-thioureido)diphenyl)-thioureido]propanedioic acid dihydrazide (MalH-(PEG)nB); cystic fibrosis with forms of male infertility, secretory diarrhea | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2008-08-19 | — | — | US | claimed |
| US-20080171793-A1 | MACROMOLECULAR CONJUGATES OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR PROTEIN INHIBITORS AND USES THEREFOR | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2008-07-17 | — | — | US | claimed |
| WO-2008079897-A2 | MACROMOLECULAR CONJUGATES OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR PROTEIN INHIBITORS AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2008-07-03 | — | — | WO | claimed |
| EP-1740532-A2 | HYDRAZIDE-CONTAINING CFTR INHIBITOR COMPOUNDS AND USES THEREOF | The Regents of the University of California (US) | 2007-01-10 | — | — | EP | claimed |
| US-20050239740-A1 | Hydrazide-containing CFTR inhibitor compounds and uses thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2005-10-27 | — | — | US | claimed |
| WO-2005094374-A2 | HYDRAZIDE-CONTAINING CFTR INHIBITOR COMPOUNDS AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2005-10-13 | — | — | WO | claimed |
| US-8552067-B2 | poly(imino-keto-methylene/amine) derivatives as a bioactive part in conjugates; diarrhea caused by pathogens: Vibrio cholerae, Clostridium difficile, Escherichia coli, Shigella, Salmonella, rotavirus; or enterotoxins: cholera toxin, E. coli toxin, Salmonella toxin | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-10-08 | — | — | US | disclosed |
| US-20110119775-A1 | HYDRAZIDE-CONTAINING CFTR INHIBITOR COMPOUNDS AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-05-19 | — | — | US | disclosed |
| US-7888332-B2 | Hydrazide-containing CFTR inhibitor compounds and uses thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-02-15 | — | — | US | disclosed |
| EP-2117601-A2 | MACROMOLECULAR CONJUGATES OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR PROTEIN INHIBITORS AND USES THEREOF | The Regents of the University of California (US) | 2009-11-18 | — | — | EP | disclosed |
| WO-2008079897-A2 | MACROMOLECULAR CONJUGATES OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR PROTEIN INHIBITORS AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2008-07-03 | — | — | WO | disclosed |
| CN-1960966-A | Hydrazide-containing CFTR inhibitor compounds and uses thereof | UNIV CALIFORNIA (US) | 2007-05-09 | — | — | CN | disclosed |
| EP-1740532-A2 | HYDRAZIDE-CONTAINING CFTR INHIBITOR COMPOUNDS AND USES THEREOF | The Regents of the University of California (US) | 2007-01-10 | — | — | EP | disclosed |
| US-20050239740-A1 | Hydrazide-containing CFTR inhibitor compounds and uses thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2005-10-27 | — | — | US | disclosed |
| WO-2005094374-A2 | HYDRAZIDE-CONTAINING CFTR INHIBITOR COMPOUNDS AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2005-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050239740-A1 | Hydrazide-containing CFTR inhibitor compounds and uses thereof | CFTR, ABCC5, SLC9A5 | CA1 1969/4885CA2 329/4885CA4 815/4885 |
| US-20110119775-A1 | HYDRAZIDE-CONTAINING CFTR INHIBITOR COMPOUNDS AND USES THEREOF | CFTR, ABCC5, SLC9A5 | CA1 1969/4885CA2 329/4885CA4 815/4885 |
| US-20080171793-A1 | MACROMOLECULAR CONJUGATES OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR PROTEIN INHIBITORS AND USES THEREFOR | CFTR, SLC47A1, SLC47A2 | CA1 4792/4885CA2 4162/4885CA4 4616/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.